Based on these results, derazantinib is being assessed in the phase II FIDES-01 trial evaluating the FGFR inhibitor in pretreated iCCA patients (NCT03230318); in this study, one arm includes patients with FGFR2 gene fusions, while the second cohort presents patients with FGFR2 mutations or amplifications. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.